Skip to main content
All lobbying filings

PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION

Lobbying for PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION · no change

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$3,189,666.00
What this organization spent lobbying with its own staff. Reported using C: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 5
  • Centers For Medicare and Medicaid Services (CMS)
  • Executive Office of the President (EOP)
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 12
  • HR 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
  • HR 4317
    PBM Reform Act of 2025
  • HR 6609
    Pharmacists Fight Back in Medicare and Medicaid Act
  • S 927
    Protecting Pharmacies in Medicaid Act
  • S 882
    Patients Before Middlemen Act
  • S 3345
    PBM Price Transparency and Accountability Act
  • HR 3164
    Ensuring Community Access to Pharmacist Services Act
  • HR 2214
    DRUG Act
  • HR 6610
    Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
  • S 3389
    Lowering Health Care Costs for Americans Act
  • S 3264
    More Affordable Care Act
  • S 526
    Pharmacy Benefit Manager Transparency Act of 2025
 Lobbying activity 3
Medicare/Medicaid

H.R. 5371; Continuing Appropriations and Extension Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid S. 927; Protecting Pharmacies in Medicaid Act S. 882; Patients Before Middlemen Act S. 3345; PBM Price Transparency and Accountability Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation

Health Issues

H.R. 5371; Continuing Appropriations and Extension Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 3389; Lowering Healthcare Costs for Americans Act S. 3264; More Affordable Care Act S. 3345; PBM Price Transparency and Accountability Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation

Pharmacy

H.R. 5371; Continuing Appropriations and Extension Act H.R. 3164; Ensuring Community Access to Pharmacist Service Act H.R. 4317; PBM Reform Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 526; Pharmacy Benefit Manager Transparency Act Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem